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Background: Sickle cell disease (SCD) is a genetic disorder common in malaria endemic areas. In endemic areas,
malaria is a major cause of morbidity and mortality among SCD patients. This suggests the need for prompt
initiation of efficacious anti-malarial therapy in SCD patients with acute malaria. However, there is no information to
date, on the efficacy or safety of artemisinin combination therapy when used for malaria treatment in SCD patients.
Methods: Children with SCD and acute uncomplicated malaria (n = 60) were randomized to treatment with
artesunate-amodiaquine (AA), or artemether-lumefantrine (AL). A comparison group of non-SCD children (HbAA
genotype; n = 59) with uncomplicated malaria were also randomized to treatment with AA or AL. Recruited children
were followed up and selected investigations were done on days 1, 2, 3, 7, 14, 28, 35, and 42. Selected clinical and
laboratory parameters of the SCD patients were also compared with a group of malaria-negative SCD children
(n = 82) in steady state.
Results: The parasite densities on admission were significantly lower in the SCD group, compared with the
non-SCD group (p = 0.0006). The parasite reduction ratio (PRR) was lower, clearance was slower (p < 0.0001), and
time for initial parasitaemia to decline by 50 and 90% were longer for the SCD group. Adequate clinical and
parasitological response (ACPR) on day 28 was 98.3% (58/59) in the SCD group and 100% (57/57) in the non-SCD
group. Corresponding ACPR rates on day 42 were 96.5% (55/57) in the SCD group and 96.4% (53/55) in the
non-SCD group. The fractional changes in haemoglobin, platelets and white blood cell counts between baseline
(day 0) and endpoint (day 42) were 16.9, 40.6 and 92.3%, respectively, for the SCD group, and, 12.3, 48.8 and
7.5%, respectively, for the non-SCD group. There were no differences in these indices between AA- and AL-treated
subjects.
Conclusions: The parasite clearance of SCD children with uncomplicated malaria was slower compared with
non-SCD children. AA and AL showed similar clinical and parasitological effects in the SCD and non-SCD groups.
The alterations in WBC and platelet counts may have implications for SCD severity.
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Sickle cell disease (SCD) is the most common mono-
genic disease worldwide. SCD is an autosomal recessive
condition that results from substitution of glutamic acid
with valine in the sixth position of the beta-globin chain
of haemoglobin. SCD occurs in individuals homozygous
for the βS globin gene (SS) or in individuals heterozy-
gous for the βS allele and other abnormal β globin gene
alleles such as βC (SC), S β0 thalassemia, or Sβ+ thalas-
semia. SCD is associated with significant morbidity and
mortality and is characterized clinically among others,
by chronic haemolysis, vaso-occlusive events and in-
creased susceptibility to infections. The highest frequen-
cies of homozygous SCD are found in sub-Saharan
Africa, where intense malaria transmission occurs.
In endemic areas, malaria is considered a major cause of
the morbidity and mortality that SCD subjects experience.
A linkage exists between the presence of sickle haemoglo-
bin (HbS) and protection from malaria in the heterozy-
gous state [1-3]; however, the homozygous (HbSS) state
may be associated with increased susceptibility to malaria
[4,5]. Malaria has been cited as a precipitating cause of
acute crises in adults with SCD [6], and as a major cause
of frequent hospitalization [7], as well as poor outcome [8]
among children with SCD. Even though evidence from re-
cent studies indicates that overall prevalence of malaria in
SCD subjects is comparatively low, it has been shown that
among hospitalized SCD patients mortality is higher
among those with malaria compared with those without
[9-14]. These considerations suggest that prompt initiation
of efficacious anti-malarial therapy among acutely ill SCD
patients with confirmed malaria is important. However,
there is paucity of information on the effects of anti-
malarial treatment in SCD patients with acute malaria in
general, and no report to date on the efficacy or safety of
currently recommended first-line malaria treatments, arte-
misinin combination therapy (ACT), when used for treat-
ment in SCD patients with malaria.
It is possible that response to anti-malarial therapy
may differ between SCD and non-SCD subjects under-
going anti-malarial treatment. Indeed, plasma chloro-
quine concentrations have been shown to be 2-3 fold
lower in subjects with SCD (HbSS) compared to those
with HbAA or HbAS, and chloroquine accumulation has
been shown to differ between SCD and non-SCD eryth-
rocytes in vitro [15]. Platelets and leucocytes have also
been shown to accumulate large amounts of chloroquine
[16], suggesting that conditions, such as SCD, that are
associated with thrombocytosis or leucocytosis, may in-
fluence anti-malarial drug distribution and consequently,
effective plasma concentrations. Furthermore, known
pathophysiological changes that are prevalent in SCD
patients such as malnutrition and hypoalbuminaemia
[17-19], could also alter anti-malarial drug distributionand metabolic clearance, which may influence the dis-
position of selected drugs in patients with these changes.
In the present study, the efficacy of artesunate-
amodiaquine (AA) and artemether-lumefantrine (AL), the
two most commonly adopted ACT regimens across sub-
Saharan Africa, were evaluated among SCD children with
parasitologically confirmed acute uncomplicated malaria
in Accra, Ghana. Selected haematological parameters in
treated SCD children were compared with those of non-
SCD children (HbAA genotype), as well as with compar-
able haematological parameters of a group of apparently
well, microscopically and malaria rapid diagnostic test
(RDT)-negative SCD children in steady state.
Methods
Study site
The study was conducted at the Outpatients Department
(OPD) and Paediatric Sickle Cell Clinic of the Department
of Child Health (DCH), Korle Bu Teaching Hospital
(KBTH), between January 2010 and December 2011. The
KBTH is a 1,600-bed tertiary referral hospital in Accra,
Ghana. Malaria transmission occurs all year in Ghana,
peaking in July-August immediately after the major rain-
fall season. The prevalence of malaria parasitaemia in
Accra ranges between 6 and 22% (average 14.8%) depend-
ing on the community [20]. The sickle cell trait occurs in
up to 25% of the population [21] and an SCD prevalence
of 2% has been reported among newborns in Ghana [22].
The DCH is a referral centre within KBTH for chil-
dren aged less than 13 years with acute or chronic med-
ical and surgical conditions. The OPD is the first point
of call for referred cases to the DCH. The OPD has an
average yearly attendance of 36,000, and is divided into
an acute care outpatients and specialty clinics. The
Paediatric Sickle Cell Clinic is one of the specialty clinics
at the DCH and has about 5,000 SCD patients below
13 years of age registered. The Paediatric Sickle Cell
Clinic provides routine and follow-up care for children
with SCD. The Clinic is held once a week and has an
average weekly attendance of about 60-70. Aside from
the Clinic, SCD children with acute illness are seen at
the Paediatric Emergency Department 24 hours a day
throughout the week.
Study population and design
Children of known SCD status registered at the Paediat-
ric Sickle Cell Clinic, who presented to the Paediatric
Emergency Department, or the Paediatric Sickle Cell
Clinic with an acute febrile illness were referred to the
study team. A study physician examined the patient and
recruited subjects if study criteria were fulfilled. At the
adjoining primary care facility (Korle Bu Polyclinic) chil-
dren not known to have SCD presenting with an acute
febrile illness were also referred to the study team and
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known SCD children visiting the Paediatric Sickle Cell
Clinic for routine scheduled follow-up visits, who were
determined to be in steady state on the day of visit (n =
82), were also recruited for the purpose of comparing se-
lected haematological indices between malaria-positive
and malaria-negative SCD children.
Criteria for inclusion
Inclusion criteria for the study were: child of confirmed
SCD status aged six months to 12 years with an acute fe-
brile illness (history of fever within the previous
72 hours, or an axillary temperature ≥37.5°C at presenta-
tion); Plasmodium falciparum infection of parasite dens-
ity <200,000/μL; and, willingness of the accompanying
parent/guardian to comply with the study procedures
and follow-up schedule. Exclusion criteria were: symp-
toms or signs of severe malaria; known intolerance or al-
lergy to study medications; and, reported treatment with
any of the study drugs one month preceding enrolment.
The inclusion and exclusion criteria for the non-SCD
(HbAA) children were the same as for the SCD children
apart from haemoglobin genotype. The SCD children in
steady state were children with confirmed SCD status
registered at the Paediatric Sickle Cell Clinic who were
asymptomatic and were visiting the Clinic for routine
scheduled evaluations. These children had a negative blood
film and negative malaria RDT result on the day of recruit-
ment. A standardized evaluation was done for assessing
and recording presenting symptoms and clinical signs and
for recording initial laboratory investigations.
Randomization and treatment allocation
A computer-generated simple randomization scheme
was prepared in advance. Allocated treatments were kept
in sealed, opaque envelopes which were opened after
completion of all formal enrolment procedures and were
then administered.
Treatment administration
Artesunate-amodiaquine (Coarsucam®, Sanofi Aventis,
France; 25/50/100 mg artesunate and 67.5/135/270 mg
amodiaquine), single daily dose, was administered for
three days according to body weight: ≥4.5- < 9 kg (25 mg/
67.5 mg), one tablet/dose; ≥9- < 18 kg (50 mg/135 mg),
one tablet/dose; ≥18- < 36 kg (100 mg/270 mg), one tab-
let/dose; ≥36 kg (100 mg/270 mg), two tablets/dose.
Artemether-lumefantrine (Coartem®, Novartis Pharma AG,
Basel, Switzerland; 20 mg artemether and 120 mg lumefan-
trine) was administered at zero and eight hours on the first
day, and then twice daily for two subsequent days according
to body weight: 5-14 kg, one tablet/dose; 15-24 kg, two tab-
lets/dose; 25-34 kg, three tablets/dose; 35 kg and over, four
tablets/dose. All drug doses were administered by studynurses at the clinic. At the clinic, children were observed
for one hour after each drug administration. Treatments
were re-administered if the child vomited within the obser-
vation period. Children who vomited the re-administered
dose were withdrawn.Follow-up
Recruited subjects were followed up on days 1, 2, 3, 7,
14, 28, 35, and 42 and on any other day outside the
scheduled follow-up days if they became ill or had any
health concerns. Children who missed their scheduled
day 14, 28 or 42 follow-up appointments were seen on
days 15, 29 or 43, respectively. Follow-up assessments
consisted of a standardized evaluation for assessing per-
sistence of presenting symptoms or clinical signs (or for
new/emergent symptoms or signs), physical examin-
ation, and laboratory investigations, described below.Laboratory investigations
Venous blood was collected into EDTA and heparinized
sample tubes on days 0, 3, 7, 14, 28, and 42. On follow-
up days 1 and 2, only a finger prick sample for a blood
smear for malaria microscopy was done. Malaria parasit-
aemia (expressed as parasites per microlitre of whole
blood) was determined in Giemsa-stained thick blood
films. Parasite density was determined by counting the
number of asexual stage parasites relative to 200 white
blood cells (WBC), and multiplied by the measured
WBC count. Each slide was read independently by two
microscopists and the average of two readings recorded.
Approximately 10% of all slides were read by a third ex-
pert microscopist who was independent of the study.
Any discrepancies in the readings were checked with all
three microscopists present and a consensus reached.
RDT for the histidine-rich protein 2 (First Response®, Prem-
ier Medical Corporation Ltd, India) and parasite lactic de-
hydrogenase (Optimal®, Diamed, Basel, Switzerland) were
done according to the manufacturers’ instructions. The
total WBC and differential counts were measured by means
of an automated haematology analyzer (Sysmex KX-21 N,
Sysmex Inc, USA). Clinical chemistry parameters were
measured, using a chemistry analyzer (Vitros® Systems, Or-
tho Clinical Diagnostics, USA). A nested PCR method was
used to analyse polymorphisms in the genes coding for the
merozoite surface protein (MSP) 1 and 2 to distinguish
between recrudescent and new infections [23,24]. The
plasma concentrations of amodiaquine and its metabolites
(desethylamodiaquine; bis-desethylamodiaquine) and lume-
fantrine and its metabolites (desbutyllumefantrine) were
measured by means of a high performance liquid chroma-
tographic (HPLC) method [25]. The SCD or HbAA status
of recruited subjects was determined by a sodium metabi-
sulphite test and alkaline haemoglobin electrophoresis.
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The primary endpoint was the parasite clearance rate on
days 1, 2 and 3 of treatment, determined by the parasite
reduction ratios (PRR), and the time for initial parasit-
aemia to decline by 50% (PC50), and by 90% (PC90).
The rationale for choosing a primary parasitological
endpoint was based on results from previous studies,
which have shown consistently high (>95%) overall cure
rates (on day 28 or 42) after treatment with either AA or
AL [26-28]. These high cure rates for both ACT regi-
mens make it unlikely that a clinically important differ-
ence would be detected between the two ACT regimens
on day 28 or 42. However, as indicated, underlying dis-
ease may influence the disposition of anti-malarial drugs
among SCD and non-SCD patients. These may influence
effective plasma concentrations and possibly treatment
response in the initial days (1-3) of treatment.
Other outcome measures included parasitaemia recur-
rence over the follow-up period after initial clearance and
changes in selected haematological profiles in the respect-
ive groups during follow-up. In the context of SCD, the
extent of changes in parameters such as haemoglobin, leu-
cocytes, neutrophils, and platelets could have important
ramifications for disease-related morbidity. Other second-
ary outcome measures included day 28 and 42 cure rates,
classified as early treatment failure (ETF), late clinical fail-
ure (LCF), late parasitological failure (LPF), or adequate
clinical and parasitological response (ACPR), according to
the WHO 2005 guidelines [29].
Adverse events were defined as any untoward medical
occurrence, irrespective of its suspected relationship to
study medications according to International Conference
on Harmonization (ICH) guidelines.
Statistical analyses
The study was designed to detect a difference in parasite
clearance and fractional reduction in parasite count
(PRR; PC50; PC90) between the SCD and non-SCD
groups. A sample size of 27 per group was sufficient to
detect, at 90% power and 95% confidence, a 30% differ-
ence in parasite clearance, or at least a two-fold change
in PRR between the SCD and non-SCD groups on day 2.
The PRR was defined as the ratio of the parasite count
before treatment to the parasite count on days 1, 2 or 3.
Time to 50 and 90% parasite clearance were obtained
from the intercept on a plot of parasitaemia versus time.
A random-effect generalized least square regression
method was used to compare parasite densities between
the SCD and non-SCD groups on successive days. The
parasite clearance rates on the specific days were also
compared, using survival analysis. Categorical variables
were compared, using the Chi square test with Yates’s
correction, or the Fisher’s exact test as appropriate. Con-
tinuous variables were compared, using the student’s t-test, or one-way analysis of variance, or the Kruskall-
Wallis test, as appropriate. For the survival analysis,
subjects who did not complete 42 days of follow-up
were censored on their last follow-up date. Probability
values <0.05 were considered significant. Data were ana-
lysed using Stata™ (Version 10).
Ethics
Ethical approval for the study was granted by the Ethical
and Protocol Review Committee of the University of
Ghana Medical School. Written, informed consent was




A total of 648 SCD children presenting with acute febrile
illness at the OPD and Paediatric Sickle Cell Clinic, DCH,
were screened for inclusion. Of those screened, 60 subjects
with confirmed P. falciparum malaria fulfilled inclusion
criteria and were randomized to treatment with AA (n =
28), or AL (n = 32). The SCD genotype distributions
among the recruited subjects were: SS, n = 43 (71.66%);
SC, n = 11 (18.33%); SS/SD, n = 5 (8.3%); and, Sβthal, n = 1
(1.6%). A total of 243 non-SCD (HbAA) children present-
ing with an acute febrile illness were screened at the Korle
Bu Polyclinic for inclusion, out of which 59 with con-
firmed P. falciparum uncomplicated malaria were ran-
domized to treatment with AA (n = 31) or AL (n = 28).
The flow of subjects through the study is shown (Figure 1).
A total of 82 SCD children in steady state presenting to
the Paediatric Sickle Cell Clinic for their scheduled routine
evaluation visits and with a negative blood film as well as
negative RDT test results were recruited.
Admission parameters
The baseline admission clinical and laboratory parameters
were significantly different between the malaria positive-
SCD and malaria positive-non-SCD (HbAA) groups
(Table 1). Within the SCD group, the mean baseline ad-
mission characteristics between AA and AL treated sub-
jects (age [years], 7.71 vs 7.60; weight [kg], 22.80 vs 23;
temperature [°C], 37.83 vs 38.09; parasite density [/μL],
1,012 vs 1,408; haemoglobin [g/dL], 6.71 vs 6.40; WBC
[×103 L], 23.87 vs 24.04; and platelets [×103L], 263.11 vs
246.56) were not statistically significant. Selected charac-
teristics of the SCD-steady state subjects were significantly
different from that of the malaria-positive SCD patients
(Table 2).
Presenting symptomatology
The predominant presenting symptom for both groups was
a history of fever. However, the proportion of SCD subjects
presenting with elevated temperature at admission was
Figure 1 Trial profile. SCD = sickle cell disease; HbAA = non-SCD; AA = artesunate-amodiaquine; AL = artemether-lumefantrine.
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among the SCD subjects were mostly vaso-occlusive
complex-related (Table 3). The reported duration of symp-
toms of subjects in the SCD group ranged from one to
eight days (mean (SD), 2.72 (1.67)), while reported symp-
tom duration among the non-SCD group ranged between
one and 14 days (mean (SD) 3.60 (2.67)).
Parasite clearance: SCD versus non-SCD groups
The parasite clearance of the SCD subjects appeared
slower, compared with the non-SCD group (Figure 2). A
random-effect generalized least squares regression ana-
lysis showed the clearance rate of the SCD group to beTable 1 Admission characteristics of sickle cell disease
(SCD) or non-SCD (HbAA) subjects with uncomplicated
malaria
SCD (n = 60) HbAA (n = 59) p
Age* (years) 7.92 (6.98-9.98) 5.45 (4.67-6.35) 0.001
Weight (kg) 23.18 (19.11) 20.54 (8.34) 0.077
Temperature (°C) 37.90 (1.12) 38.62 (1.12) 0.001
Jaundice (n) 42 (79.2 %) 4 (6.7 %) < 0.001
Spleen size (cm) 1.27 (2.73) 0.20 (0.81) 0.008
Liver size (cm) 3.42 (4.70) 0.43 (1.32) < 0.001
Parasite density* (/μL) 1,197 (645-2221) 11,774 (5256-26375) 0.0006
Haemoglobin (g/dL) 6.56 (2.22) 9.71 (2.16) <0.0001
WBC (109/L) 23.95 (18.45) 10.21 (5.92) <0.0001
Platelet count (109/L) 254.8 (133.9) 154.9 (106.1) <0.0002
Data are means (SD), except *geometric mean (95% CI), SCD = sickle cell
disease; HbAA = non-SCD.significantly different from the non-SCD group (Wald p-
value < 0.0001). The PRR was lower, and the times for
parasitaemia to decline, (by 50 and 90%) as determined
from the intercept of the parasite clearance curve, was
longer for the SCD group compared with the non-SCD
group (Table 4). However, using Cox regression analysis,
individual parasite clearance rate per day was 0.536 (95%
CI, 0.408-0.704) among the SCD subjects compared with,
0.448 (95% CI, 0.328-0.614) among the non-SCD subjects
(Mantel Haenszel rate ratio, 0.836, 95% CI, 0.552-1.267,
p = 0.39). Similar results were obtained, using survival ana-
lysis (log rank test for equality of survival functions, p =
0.10, Figure 3).
Parasite clearance: AA versus AL among SCD subjects
Within the SCD group, the parasite clearance rate per
day was 0.58 (95% CI, 0.393-0.849) for the AA-treated
group, compared with 0.50, (95% CI, 0.340-0.734) for
the AL-treated group (Mantel-Haenszel rate ratio, 0.865,
95% CI, 0.502-1.492, p = 0.60). Similar results were ob-
tained, using survival analysis (log rank test for equality
of survival functions, p = 0.30, Figure 3).
Cure rates on day 28 and 42: SCD versus non-SCD groups
The proportion of evaluable subjects with uncorrected
ACPR on day 28 was 98.3% (58/59) in the SCD group,
and 100% (57/57) in the non-SCD group, respectively.
The corresponding ACPR rates on day 42 were 96.5%
(55/57) in the SCD group and 96.4% (53/55) in the
HbAA group. The PCR-corrected ACPR rates on day 42
were 98.2% (56/57) in the SCD group and 98.2% (54/55)
in the non-SCD group (Table 5).
Table 2 Admission characteristics of sickle cell disease (SCD) subjects with malaria versus that of SCD subjects in
steady state
SCD-malaria (n = 60) SCD Steady state (n = 82) p
Age* (years) 7.92 (6.98-9.98) 6.86 (6.15-7.65) 0.072
Weight (kg) 23.18 (19.11) - -
Temperature (°C) 37.90 (1.12) - -
Jaundice (n) 42 (79.2 %) - -
Spleen size (cm) 1.27 (2.73) - -
Liver size (cm) 3.42 (4.70) - -
Parasite density* (/μL) 1,197 (645-2,221) - -
Haemoglobin (g/dL) 6.56 (2.22) 8.14 (1.59) <0.0001
WBC (109/L) 23.95 (18.45) 13.76 (4.34) <0.0001
Platelet count (109/L) 254.8 (133.9) 413.122 (184.38) <0.0001
Data are means (SD), except *geometric mean (95% CI), SCD = sickle cell disease; SCD Steady state = sickle cell disease (malaria-negative) subjects in steady state.
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SCD subjects
Within the SCD group, the proportion of evaluable AA-
treated subjects with ACPR (uncorrected) was 96.4%
(27/28) on day 28 and 92.6% (25/27) on day 42. The cor-
responding ACPR rates in the non-SCD group were
100% (30/30) on day 28 and 100% (29/29) day 42. The
proportion of AL-treated subjects with ACPR in the
SCD group was 100% (31/31) on day 28 and 100% (30/
30) on days 28 and 42, respectively. The corresponding
ACPR rates in the non-SCD group were 100% (27/27)
on day 28 and 92.3% (24/26) on day 42, respectively.Table 3 Frequency of presenting symptoms and signs among
with uncomplicated malaria
Symptom/sign SCD (n = 60)
Fever* 33
Bone and/or joint pain 24
Abdominal pain 11
Headache 10












Swollen lower limb 1
*Fever = measured temperature ≥ 37.5°C; majority of subjects presented with moreSelected characteristics of children with recurrent para-
sitaemia during follow-up are shown (Table 6).
Selected haematological parameters on admission and
during follow-up
The mean haemoglobin levels of the SCD-malaria positive
subjects were lower than those of the non-SCD (HbAA)-
malaria-positive subjects on admission and all scheduled
follow-up days (Figure 4). Among the SCD subjects, the
mean haemoglobin levels of the AA-treated and AL-treated
subjects were similar (Figure 5). The platelet counts on ad-
mission and follow-up were significantly higher (except onsickle cell disease (SCD) and non-SCD (HbAA) children


















than one symptom; therefore, data is not 100% cumulative.
Figure 2 Parasite clearance versus time (days) in the sickle cell disease (SCD) and non-SCD (HbAA) groups. SCD-mal + = sickle cell disease
subjects with acute malaria group; Non-SCD (HbAA)-mal + = non-SCD subjects with acute malaria group.
Adjei et al. Malaria Journal 2014, 13:369 Page 7 of 14
http://www.malariajournal.com/content/13/1/369days 3 and 7) in the SCD-malaria-positive subjects com-
pared with the non-SCD (HbAA) malaria-positive subjects
(Figure 6). Among the SCD subjects, the platelet counts on
admission and follow-up were similar for the AA-treated
and AL-treated subjects (Figure 7). The total WBC levels
of the SCD-malaria-positive subjects on admission and
follow-up were higher than those of the non-SCD subjects
(Figure 8). Among the SCD patients, total WBC counts on
admission and follow up were similar for the AA-treated
and AL-treated subjects (Figure 9). The platelet counts of
the SCD-steady state subjects were significantly higher than
those of the SCD-malaria positive subjects on admissionTable 4 Parasite reduction ratios in the various groups
Group Day of treatment Parasite density
(geometric mean)
P
SCD Day 0 1197 -
Day 1 788 1
Day 2 599 1
Day 3 226 5
HbAA Day 0 11,774 -
Day 1 2,811 4
Day 2 118 9
Day 3 32 3
SCD-AA Day 0 1,012 -
Day 1 684 1
Day 2 2,135 0
Day 3 64 1
SCD-AL Day 0 1,408 -
Day 1 869 1
Day 2 228 6
Day 3 2840 0
SCD = sickle cell disease, HbAA = non-SCD, SCD-AA = SCD subjects treated with arte
lumefantrine.while the admission WBC count of the SCD-malaria
patients was higher than those of the SCD steady state
subjects (Table 2).
Haematological index changes
The fractional change differences in the selected haema-
tological indices (WBC, platelets, haemoglobin) between
admission (day 0, acute illness) and endpoint (day 42, re-
covery/convalescence) in the SCD and non-SCD groups
were WBC (92.3%, (SCD) versus 7.5%, (non-SCD); plate-
lets (40.6%, (SCD) versus 48.8%, (non-SCD); and, haemo-
globin (16.9%, SCD versus 12.3%, (non-SCD), respectively.RR Time to 50 % parasite
density (days)















sunate-amodiaquine, SCD-AL = SCD subjects treated with artemether-
Figure 3 Survival analysis showing parasite clearance per individual in the respective groups. SCD-AA = artesunate-amodiaquine-treated
sickle cell disease subjects with acute malaria; SCD-AL = artemether-lumefantrine-treated sickle cell disease subjects with acute malaria; non-SCD = non
sickle cell disease (haemoglobin genotype AA) subjects with acute malaria.
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those with recurrent parasitaemia
The individual plasma DEAQ concentrations in the two
AA-treated subjects who experienced recurrent parasit-
aemia were 20 ng/ml and 21 ng/ml, respectively.Adverse events
Adverse events emerging during and after treatment
overlapped substantially with known malaria or SCD
symptomatology, could not be attributed to administered
treatments, and were in most cases adjudged as unre-
lated to study medications.Table 5 Efficacy outcomes on day 28 and 42 in the SCD
and HbAA groups
Day 28 SCD HbAA
Uncorrected PCR-corrected Uncorrected PCR-corrected
ACPR 58 59 57 57
ETF 0 0 0 0
LCF 0 0 0 0
LPF 1 0 0 0
Day 42 SCD HbAA
ACPR 55 56 53 54
ETF 0 0 0 0
LCF 0 0 0 0
LPF 2 1 2 1
ACPR = adequate clinical and parasitological response, ETF = early treatment
failure, LCF = late clinical failure, LPF = late parasitological failure, SCD = sickle
cell disease, HbAA = non-SCD.Discussion
This study reports treatment response of paediatric SCD
patients with acute uncomplicated malaria to recommended
first-line ACT regimens. In particular, the study reports
for the first time systematically collected data on parasite
clearance and on selected haematological parameters
(haemoglobin, WBC, platelets) in SCD children undergo-
ing ACT treatment.
The data showed significantly lower parasite densities
on admission, slower clearance dynamics, lower PRR
values, and longer time to 50 and 90% parasite clearance
in the SCD, compared with the non-SCD children. The
significantly lower parasite densities among SCD pa-
tients compared with non-SCD patients has been re-
ported in previous studies [2,30,31]. This is thought to
result from the protective effect of the sickle haemoglo-
bin [3,32,33], via mechanisms that include reduced para-
site growth [34], enhanced phagocytosis [35,36], and
removal of parasitized cells - through innate or acquired
immunological processes [2]. The degree of protection
conferred by the sickle phenomenon has been shown to
correlate with intracellular HbS concentration implying
a greater propensity to protection in homozygous sub-
jects. The protective effect of the sickle haemoglobin on
malaria has also been ascribed to aberrant host actin re-
modelling [37], and to accelerated breakdown of haem
oxygenase, which is strongly induced by the sickle
haemoglobin [38]. More recently, the role of dysregu-
lated microRNA activity, where growth inhibitory host
microRNAs are translocated into the parasite, or fuse
with extant parasite mRNA transcripts to inhibit transla-
tion of enzymes critical for parasite development has
also been described [39].
Table 6 Selected characteristics of subjects with recurrent parasitaemia in the SCD and non-SCD groups
Age (yrs) Genotype Admission parasitaemia Day of recurrence Treatment received PCR result Day 7 drug levels
9 SS 640 21 AA New infection DQ-21 ng/ml
4 SS/SD 2480 35 AA Recrudescence DQ-20 ng/ml
2.5 HbAA 79520 42 AL Recrudescence DL- ND
7 HbAA 63400 42 AL New infection DL - ND
SS = sickle cell anaemia, HbAA = non-SCD, AA = artesunate-amodiaquine, AL = artemether-lumefantrine, DQ = desethylamodiaquine, DL = desbutyllumefantrine,
ND = not done.
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http://www.malariajournal.com/content/13/1/369The lower PRR and longer time to 50 and 90% parasite
clearance among the SCD-malaria patients compared
with non-SCD malaria patients has not been previously
reported. This is partly because there have been no pre-
vious studies reporting parasite clearance changes
among SCD patients undergoing anti-malarial treatment.
The apparent disparity between the slower clearance,
lower PRR’s and time to 50 and 90% clearance of the
SCD versus non-SCD group data on one hand, and the
comparable clearance rates between the two groups
from the Cox regression analysis may reflect a conver-
gence effect due to the significant initial parasitaemia
differences between the two groups. The several-fold dif-
ference in admission parasite density between the two
groups makes direct comparison problematic. However,
the lower PRR and clearance rate in the SCD group in
spite of a lower initial parasitaemia suggests a true
between-group difference. The cure rates on day 28 or
42 were high for both the SCD and non-SCD groups.
This is consistent with the high efficacy rates for AA
and AL that have been reported across sub-SaharanFigure 4 Haemoglobin levels on admission and follow up between th
means and 95% confidence intervals (error bars). SCD = sickle cell disease sAfrica [26-28,40]. Indeed, AA and AL have both been
associated with high day 28 cure rates when used for
treatment of uncomplicated malaria, even among chil-
dren with underlying immune-deficiency [41-43]. It is
reasonable to expect therefore, that the lower PRR in the
SCD group is unlikely to translate overall into difficulties
with treatment. However, the implications of this finding
to symptom resolution and malaria-related morbidity in
SCD patients are unclear.
The individual plasma drug concentrations of DEAQ
(20 ng/ml; 21 ng/ml) in the two AA-treated subjects with
recurrent parasitaemia were lower than the mean plasma
concentrations (115 ng/ml; 156.6 ng/ml) [44,45] that has
been reported for (non-SCD) children treated with these
regimens. It has been suggested that an in vivo day 3
DEAQ concentration of 135 ng/ml is the minimum level
required for adequate treatment efficacy [45]. This sug-
gests that these cases of recurrent parasitaemia are likely
due to inadequate exposure, rather than parasite resist-
ance. It cannot also be ruled out that low plasma DEAQ
concentrations may result from variable disposition ofe sickle cell disease and non-sickle cell disease subjects. Data are
ubjects; HbAA = non-sickle cell disease subjects.
Figure 5 Haemoglobin levels on admission and follow-up between the artesunate-amodiaquine- and artemether-lumefantrine-treated
sickle cell disease subjects. Data are means and 95% confidence intervals (error bars). SCD-AA = artesunate-amodiaquine-treated sickle cell
disease subjects; SCD-AL = artemether-lumefantrine-treated sickle cell disease subjects.
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http://www.malariajournal.com/content/13/1/369these anti-malarials among SCD patients. This may sug-
gest that pharmacokinetic studies of ACT regimens in
populations with other significant co-morbidities may be
warranted.
The lower fever incidence and higher WBC counts in
the SCD group at presentation may present specific diffi-
culties, especially with respect to diagnosis of diseases of
bacterial origin. However, a raised WBC in SCD is also a
recognized risk factor for complications ranging fromFigure 6 Platelet counts on admission and follow-up between the sic
means and 95% confidence intervals (error bars). SCD = sickle cell disease sacute chest syndrome, silent cerebral infarction, clinically
overt stroke, and early death [46-52]. In this respect, the
raised WBC at the acute illness stage among the SCD
patients may represent an additional (malaria-related)
prognostic indicator.
The majority of SCD subjects presented on admission
with symptoms and signs consistent with vaso-occlusive
complex (VOC) -related phenomena. Vaso-occlusion cri-
sis is a hallmark of SCD but the mechanism(s) responsiblekle cell disease and non-sickle cell disease subjects. Data are
ubjects; HbAA = non-sickle cell disease subjects.
Figure 7 Platelet counts on admission and follow-up between the artesunate-amodiaquine- and artemether-lumefantrine-treated sickle
cell disease subjects. Data are means and 95% confidence intervals (error bars). SCD-AA = artesunate-amodiaquine-treated sickle cell disease
subjects; SCD-AL = artemether-lumefantrine-treated sickle cell disease subjects.
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http://www.malariajournal.com/content/13/1/369for triggering VOC in SCD is likely a result of complex
interplay of precipitating factors at multiple stages. How-
ever, it has been shown that SCD subjects in VOC have
higher levels of pro-inflammatory cytokines compared
with those in steady state [53]. Since malaria has been
shown to be a precipitating factor for VOC in SCD pa-
tients [6], it is plausible that, the chronic inflammatory
status in the SCD malaria-positive patients could influ-
ence parasite clearance directly, or indirectly, throughFigure 8 Total white blood cell counts on admission and follow-up b
Data are means and 95% confidence intervals (error bars). SCD = sickle cellyet- undetermined action of anti-malarial drugs in SCD
patients.
It is possible that the observed PRR differences be-
tween the SCD and non-SCD patients reflect intrinsic
differences in peripheral blood components and specific
variations in cell types between SCD and non-SCD sub-
jects. It is usually assumed that malaria parasites and
leucocytes are both distributed evenly on a thick smear;
however, it has been shown that in cases of scantyetween the sickle cell disease and non-sickle cell disease subjects.
disease subjects; HbAA = non-sickle cell disease subjects.
Figure 9 Total white blood cell counts on admission and follow-up between the artesunate-amodiaquine- and artemether-lumefantrine-
treated sickle cell disease subjects. Data are means and 95% confidence intervals (error bars). SCD-AA = artesunate-amodiaquine-treated sickle cell
disease subjects; SCD-AL = artemether-lumefantrine-treated sickle cell disease subjects.
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http://www.malariajournal.com/content/13/1/369parasitaemia, parasites tend to aggregate in a specific area
of a blood smear [54]. This suggests that parasite density
estimations based on assumption of a homogenous and,
therefore, Poisson-type distribution can result in over-
dispersion [55], which may result in over- or under-
estimation of parasitaemia.
The observed profiles for the selected haematological
indices for the non-SCD subjects (anaemia, thrombo-
cytopaenia and modest neutrophilia-driven leucocytosis),
are consistent with those reported for African children
with uncomplicated malaria [56,57]. The corresponding
profiles for the SCD subjects are also similar to reported
values for SCD subjects [58].
In SCD subjects, elevated platelet counts have been as-
cribed among others, to absent splenic pooling or func-
tional asplenia [59]. As a reduced platelet count is a
feature of malaria infection, the relatively lower mean
platelet counts of the SCD-malaria-positive subjects com-
pared with SCD subjects in steady state is likely due to the
malarial disease [60,61]. However, as platelet activation in
SCD contributes to a hypercoagulable state, which can re-
sult in thrombo-embolic phenomena [62], the implications
of these platelet count variations to malaria-related mor-
bidity among SCD subjects are unclear.
Conclusion
Treatment of children with uncomplicated malaria showed
lower PRR and slower parasite clearance in the SCD sub-
jects compared with non-SCD subjects. However, the
comparably high day 28 and 42 cure rates in both SCD
and non-SCD groups suggest an unlikely effect of this
finding on acute malaria management in SCD patients.There were marked variations in leucocyte and platelet
counts between acute illness and recovery stages among
the SCD patients with malaria. The overall implications of
these changes with respect to malaria-related morbidity
among SCD patients are uncertain.
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